Press release
Severe Asthma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Severe Asthma Clinical Trials
(Albany, USA) DelveInsight's, "Severe Asthma Pipeline Insight 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape.
The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Severe Asthma Treatment Landscape. Click here to read more @ Severe Asthma Pipeline Outlook [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Severe Asthma Pipeline Report
* GSK's depemokimab, a long-acting anti-IL-5 monoclonal antibody for severe asthma with type 2 inflammation, has been accepted for FDA review with a target decision date of December 16, 2025.
* In March 2025, AstraZeneca announced a study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.
* In March 2025, Upstream Bio Inc. announced a study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
* In January 2025:- AstraZeneca:- This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.
* In January 2025: Upstream Bio Inc.:- The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
* In January 2025:- Incyte Corporation:- A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
* DelveInsight's Severe Asthma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
* The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Promising Severe Asthma Therapies such as Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
Stay informed about the cutting-edge advancements in Severe Asthma treatments. Download for updates and be a part of the revolution in Respiratory Diseases care @ Severe Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Severe Asthma Emerging Drugs
* GSK3511294: GlaxoSmithKline
GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline, for the treatment of asthma. GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of severe asthma.
* BSI-045B: Biosion
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion's collaboration partner - CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.
* Mepolizumab: Bio-Thera Solutions
Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months' duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.
Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight's detailed report now! @ Severe Asthma Treatment Drugs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Severe Asthma Companies
Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Severe Asthma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Asthma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Severe Asthma Pipeline Report
* Coverage- Global
* Severe Asthma Companies- Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Severe Asthma Therapies- Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
* Severe Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Severe Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Severe Asthma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Severe Asthma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK3511294: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BSI-045B: Biosion
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Mepolizumab: Bio-Thera Solutions
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Severe Asthma Key Companies
* Severe Asthma Key Products
* Severe Asthma- Unmet Needs
* Severe Asthma- Market Drivers and Barriers
* Severe Asthma- Future Perspectives and Conclusion
* Severe Asthma Analyst Views
* Severe Asthma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-asthma-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Asthma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4112616 • Views: …
More Releases from ABNewswire
Post-Construction Cleaning Demand Rises Among Miami Renovators as The Prime Clea …
Miami homeowners and contractors are driving increased demand for professional post-construction cleaning services, with The Prime Cleaner reporting significant growth in this specialty category across South Florida.
MIAMI, FL - Demand for professional post-construction cleaning services is rising across Miami as homeowners complete renovations and contractors seek reliable cleaning partners for new builds. The Prime Cleaner has expanded its post-construction cleaning services [https://www.theprimecleaner.com/service/post-construction-cleaning] to meet the growing need.
Miami's construction and renovation…
Extending the Invisible Cord: Why Bluetooth Repeaters Are Essential for Seamless …
We live in a wireless world. Our headphones, keyboards, speakers, and even our lightbulbs connect via Bluetooth, freeing us from the tangle of cables. Yet, despite its convenience, Bluetooth has a wellknown limitation: range. The connection between a device and its source-whether it's a phone streaming music or a sensor reporting data-can stretch only so far before it stutters and drops. For homes, offices, and industrial facilities, these dead zones…
Beyond GPS: How Bluetooth Beacons Are Bridging the Gap Between Digital and Physi …
In an era dominated by GPS, it is easy to assume we have solved the problem of location tracking. We can navigate bustling cities, track lost phones, and find the nearest coffee shop with pinpoint accuracy-provided we are outside. But the moment we step indoors, the satellite signals fade, leaving a blind spot in our connected experiences.
This is where a small, unassuming piece of technology is making a massive impact:…
ECI Jewelers Introduces Streamlined Selling Experience with Same-Day Offers and …
ECI Jewelers has enhanced its luxury watch and jewelry buying service with same-day market-based offers and instant payment options for sellers nationwide. The concierge-style approach includes free valuations, full insurance coverage during transit, and expert assessment from the company's New York City Diamond District location, simplifying the selling process for owners of premium timepieces from brands like Rolex, Patek Philippe, and Audemars Piguet.
Elegant Creations Inc, operating as ECI Jewelers, has…
More Releases for Severe
PMS or PMDD? Understanding Severe Premenstrual Mood Changes
Many women notice mood shifts before their period. They may feel more emotional, tired, or irritable. This is often labeled PMS. For some, symptoms are mild and manageable. For others, they are intense and disruptive.
When mood changes become severe, especially when they affect work, school, or relationships, it may be something more serious. That condition is called PMDD.
Understanding the difference between typical premenstrual symptoms and a psychiatric condition can help…
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763
This latest report researches the industry structure, sales, revenue,…
